International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts.

By H. Dombret, J. Seymour, Aleksandra Butrym, A. Wierzbowska, D. Selleslag, J. Jang, Rajat Kumar, J. Cavenagh, A. Schuh, A. Candoni and 14 more. Blood, 2015

1,121 citations recorded by the source corpus.

Subfields: Genetics, Hematology, Molecular Biology

View Paper: https://www.semanticscholar.org/paper/5d7dea4b20c12e18f017dfad522801c84f0c5039

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Molecular Biology

1. R. Su
2. Jianjun Chen
3. Huilin Huang
4. Xiaolan Deng
5. Hengyou Weng
6. Chuan He

Citations in the corpus

• Targeting FTO suppresses cancer stem cell maintenance and immune evasion (2020, positive): “HMAs are wildly used for the treatment of patients with AML or myelodysplastic syndrome (MDS), especially in elderly patients and in those who are not eligible for allogeneic stem cell transplantation (Dombret et al., 2015; Issa et al., 2004; Yun et al., 2016).”